Apricus Biosciences Announces Proposed Public Offering of Common Stock and
SAN DIEGO, May 22, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) today announced that it intends
to offer shares of common stock and warrants in an underwritten public
offering. The Company also expects to grant the underwriters a 30-day option
to purchase additional shares of common stock and warrants to cover
over-allotments, if any. Lazard Capital Markets LLC is acting as sole
book-running manager for the offering. While the offering is expected to
price before 9:30 am EDT on May 23, 2013, the offering is subject to market
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
A registration statement relating to the common stock and warrants issued in
the offering has been filed with, and declared effective by Securities and
Exchange Commission (the "SEC"). A preliminary prospectus supplement, as well
as a final prospectus supplement, relating to the offering will be filed with
the SEC, each of which will form a part of the effective registration
statement. When available, copies of the preliminary and final prospectus
supplements and the accompanying base prospectus relating to these securities
may be obtained by visiting the SEC's website at www.sec.gov or Lazard Capital
Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via
telephone at (800) 542-0970.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros®, for the treatment of
erectile dysfunction, which will be marketed in Canada by Abbott Laboratories,
and Femprox®, a product candidate, for the treatment of female sexual arousal
This press release contains forward-looking statements, including statements
related to Apricus Biosciences, Inc.'s public offering of common stock and
warrants and the completion, timing and size of the offering that involve
risks and uncertainties. Words such as "believes," "anticipates," "plans,"
"expects," "intend," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Apricus Biosciences, Inc.'s current expectations.
Actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the proposed offering and other risks detailed in
Apricus Biosciences, Inc.'s filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and Apricus Biosciences, Inc. undertakes no
obligation to revise or update any forward-looking statements to reflect
events or circumstances after the date of this press release.
CONTACT: Apricus Bio Investor Relations:
Press spacebar to pause and continue. Press esc to stop.